BioCardia, Inc. (BCDA): Price and Financial Metrics
BCDA Stock Summary
- With a price/sales ratio of 489.05, BioCardia Inc has a higher such ratio than 98.49% of stocks in our set.
- As for revenue growth, note that BCDA's revenue has grown -79.58% over the past 12 months; that beats the revenue growth of only 1.85% of US companies in our set.
- BioCardia Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -40.01%, greater than the shareholder yield of only 5.91% of stocks in our set.
- Stocks that are quantitatively similar to BCDA, based on their financial statements, market capitalization, and price volatility, are APTX, MRKR, RESN, HRTX, and VTGN.
- BCDA's SEC filings can be seen here. And to visit BioCardia Inc's official web site, go to www.biocardia.com.
BCDA Stock Price Chart Interactive Chart >
BCDA Price/Volume Stats
|Current price||$4.05||52-week high||$8.60|
|Prev. close||$4.34||52-week low||$1.91|
|Day high||$4.31||Avg. volume||300,396|
|50-day MA||$4.29||Dividend yield||N/A|
|200-day MA||$3.10||Market Cap||66.17M|
BioCardia, Inc. (BCDA) Company Bio
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system, a percutaneous catheter delivery system for cardiovascular regenerative medicine; and Morph deflectable guides and sheaths. The company is based in San Carlos, California.
BCDA Latest News Stream
|Loading, please wait...|
BCDA Latest Social Stream
View Full BCDA Social Stream
Latest BCDA News From Around the Web
Below are the latest news stories about BioCardia Inc that investors may wish to consider to help them evaluate BCDA as an investment opportunity.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
SAN CARLOS, Calif., March 15, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, announces that CEO Dr. Peter Altman will present at Maxim Group’s Inaugural Emerging Growth Virtual Conference to be held March 17-19, 2021. Investors can view Dr. Altman’s live fireside chat presentation at 3:30pm ET on March 19 and once registered for the conference here, can listen to a corporate presentation which will be available on the conference website. Investors can also request a 1x1 meeting with Dr. Altman to be arranged following the conclusion of the conference. About BioCardia BioCardia, headquartered in San Carlos, California, is developing regenerative biologic therapies to treat cardiov...
SAN CARLOS, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA] a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced clinical leadership changes. Dr. Sujith Shetty who has been with the Company for almost two years in the capacity of Vice President of Clinical and Regulatory will assume the role of Chief Medical Officer, replacing Dr. Eric Duckers, who resigned as Chief Medical Officer of the Company to pursue other opportunities, effective as of February 15th, 2021. Simultaneous with his resignation, Dr. Duckers entered into a consulting agreement to continue to provide support for the ongoing CardiAMP Heart Failure Trial and its leadership team. Ms. Debby Holmes-Higgin who has been with the Company for ...
SAN CARLOS, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA] a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today provides an update on its cell therapy product development and 2021 milestones. BCDA-01, our CardiAMP autologous cell therapy under Phase III clinical development for the treatment of ischemic heart failure remains the Company’s top priority. The Company is targeting completion of enrollment without requiring additional financing. The trial is expected to have its next prespecified independent Data Safety Monitoring Board review in early Q3 2021.BCDA-02, our CardiAMP autologous cell therapy is under Phase III development for the treatment of chronic myocardial ischemia. First patient enrolled in the ...
SAN CARLOS, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA] a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, welcomes Krisztina Zsebo, Ph.D., a 31-year veteran of the biotech industry, to its Board of Directors following her election at BioCardia’s 2020 Annual Meeting of Stockholders in December 2020.Dr. Zsebo has extensive biotechnology experience in discovery, development, and commercialization, having raised more than $200 million to support operations and having launched breakthrough technologies and products with total annual sales exceeding $3.5 billion. She was an integral member of the Amgen team that first cloned the molecule that would become Neupogen; identified the molecule and led the Amgen research ...
BCDA Price Returns
Continue Researching BCDAHere are a few links from around the web to help you further your research on BioCardia Inc's stock as an investment opportunity:
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!